Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond

home / readout-360 / recent-updates-in-the-role-of-bispecifics-in-multiple-myeloma-highlights-from-ash-2022-and

Shaji Kumar, MD, Sandy Wong, MD, and Alexander Lesokhin, MD, review key data updates on the use of bispecific antibodies for the treatment of multiple myeloma presented at ASH 2022 and other recent meetings, and discuss how recent clinical trials have influenced treatment approaches in both the transplant-eligible and -ineligible patient populations.

EP. 1: GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 9th 2023

Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).

EP. 2: Treatment Approaches in Transplant-Eligible NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 9th 2023

Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.

EP. 3: Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 16th 2023

Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.

Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 4: Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 16th 2023

Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.

EP. 5: Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 23rd 2023

The panel reviews possible treatment approaches for patients with high-risk NDMM, and how MRD negativity affects their decision making.

EP. 6: Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 23rd 2023

Alexander Lesokhin, MD, presents data from an interim analysis of the GMMG-CONCEPT trial investigating an isatuximab-based quadruplet regimen for high-risk NDMM.

EP. 7: Comparing Quadruplet Combination Treatment Regimens in NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 30th 2023

The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.

EP. 8: Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

March 30th 2023

Shaji Kumar, MD, presents data from an updated analysis of the MAIA trial investigating daratumumab/lenalidomide/dexamethasone for transplant-ineligible NDMM.

EP. 9: Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

April 6th 2023

Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.

EP. 10: IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

Shaji Kumar, MD, Mayo Clinic;Sandy Wong, MD;Alexander Lesokhin, MD

April 6th 2023

The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.